Active — Not RecruitingPhase 4

Infant Mortality Reduction by the Mass Administration of Azithromycin

United States, Burkina Faso694,400 participantsStarted 2021-10-04

Plain-language summary

This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.

Who can participate

Age range1 Month – 11 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Community eligibility criteria: * Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins * Verbal consent of the community leader is obtained Inclusion criteria for children: * Aged 1 to 11 months * Living in one of the communities participating in the study Exclusion Criteria: Community exclusion criteria: • Inaccessible or unsafe for the study team Exclusion criteria for children: • Known allergy to macrolides

What they're measuring

All-cause mortality

Timeframe: 24 months following baseline

Trial details

NCT IDNCT04716712

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-30

View on ClinicalTrials.gov More Child Mortality trials